Literature DB >> 26022160

Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.

Yang Chen1, Zuojun Shen.   

Abstract

The antifolate drug methotrexate (MTX) is widely used in the treatment of various neoplastic diseases, including acute lymphoblastic leukemia (ALL). MTX significantly increases cure rates and improves patients' prognosis. Despite that it achieved remarkable clinical success, a large number of patients still suffer from treatment toxicities or side effects. Even to this date, chemotherapeutic regiments have not been personalized because of interindividual differences that affect MTX response, especially polymorphisms in key genes. The pharmacological pathway of MTX in cells is useful to identify gene polymorphisms that influence the process of treatment. The aim of this review was to discuss the gene polymorphisms of drug-metabolizing enzymes in the MTX pathway and their toxicities on ALL treatment.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26022160     DOI： 10.1007/s13277-015-3602-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  83 in total

1.  Coordinated effects of distal mutations on environmentally coupled tunneling in dihydrofolate reductase.

Authors:  Lin Wang; Nina M Goodey; Stephen J Benkovic; Amnon Kohen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-10       Impact factor: 11.205

2.  Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.

Authors:  Noha M El-Khodary; Sahar M El-Haggar; Manal A Eid; Emad N Ebeid
Journal:  Med Oncol       Date:  2011-06-05       Impact factor: 3.064

3.  Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia.

Authors:  Christine F Skibola; Martyn T Smith; Alan Hubbard; Barry Shane; Abby C Roberts; Graham R Law; Sara Rollinson; Eve Roman; Raymond A Cartwright; Gareth J Morgan
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Genome-wide study of methotrexate clearance replicates SLCO1B1.

Authors:  Laura B Ramsey; John C Panetta; Colton Smith; Wenjian Yang; Yiping Fan; Naomi J Winick; Paul L Martin; Cheng Cheng; Meenakshi Devidas; Ching-Hon Pui; William E Evans; Stephen P Hunger; Mignon Loh; Mary V Relling
Journal:  Blood       Date:  2012-12-11       Impact factor: 22.113

5.  Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.

Authors:  Hua-Nian Zhang; Xue-Lian He; Cheng Wang; Yang Wang; Yu-Jun Chen; Jian-Xin Li; Chang-He Niu; Ping Gao
Journal:  Pediatr Blood Cancer       Date:  2014-08-17       Impact factor: 3.167

6.  Ancestry and pharmacogenetics of antileukemic drug toxicity.

Authors:  Shinji Kishi; Cheng Cheng; Deborah French; Deqing Pei; Soma Das; Edwin H Cook; Nobuko Hijiya; Carmelo Rizzari; Gary L Rosner; Tony Frudakis; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

Review 7.  Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.

Authors:  Ying Huang
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

8.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.

Authors:  Marc Ansari; Géraldine Sauty; Malgorzata Labuda; Vincent Gagné; Caroline Laverdière; Albert Moghrabi; Daniel Sinnett; Maja Krajinovic
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

9.  [Pharmacogenomics of acute lymphoblastic leukemia].

Authors:  Marc Ansari; Geneviève St-Onge; Maja Krajinovic
Journal:  Med Sci (Paris)       Date:  2007-11       Impact factor: 0.818

10.  Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia.

Authors:  M Krajinovic; E Lemieux-Blanchard; S Chiasson; M Primeau; I Costea; A Moghrabi
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550
View more
  3 in total

1.  The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.

Authors:  Che-Pei Kung; Julia I-Ju Leu; Subhasree Basu; Sakina Khaku; Frederick Anokye-Danso; Qin Liu; Donna L George; Rexford S Ahima; Maureen E Murphy
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

2.  Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate.

Authors:  Magdalena Cwiklinska; Malgorzata Czogala; Kinga Kwiecinska; Anna Madetko-Talowska; Malgorzata Szafarz; Katarzyna Pawinska; Aleksandra Wieczorek; Tomasz Klekawka; Magdalena Rej; Konrad Stepien; Przemyslaw Halubiec; Agnieszka Lazarczyk; Karol Miklusiak; Miroslaw Bik-Multanowski; Walentyna Balwierz; Szymon Skoczen
Journal:  Front Pediatr       Date:  2020-06-16       Impact factor: 3.418

3.  Influence of Folate-Related Gene Polymorphisms on High-Dose Methotrexate-Related Toxicity and Prognosis in Turkish Children with Acute Lymphoblastic Leukemia.

Authors:  Burcu Yazıcıoğlu; Zühre Kaya; Sezen Güntekin Ergun; Ferda Perçin; Ülker Koçak; İdil Yenicesu; Türkiz Gürsel
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.